GENE ONLINE|News &
Opinion
Blog

2022-06-22| Trials & Approvals

AstraZeneca, Ionis’ ATTR Drug Edges Closer to US Approval With Latest Trial Win

by Joy Lin
Share To

AstraZeneca and Ionis’ eplontersen, a treatment for transthyretin amyloidosis, has met its primary endpoints in the Phase 3 trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTR v-PN), according to an interim analysis. Based on the results, the companies are now eyeing a New Drug Application to the US FDA later this year. 

ATTR v-PN is a progressive disease that leads to peripheral nerve damage with motor disability. Without treatment, it is usually fatal within a decade. Eplontersen is a ligand-conjugated antisense (LICA) medicine designed to reduce the production of the misfolded TTR protein that accumulates in the peripheral nerves and organs and causes the disease. 

“Amyloid transthyretin polyneuropathy is a rare and fatal disease that can affect up to 40,000 people worldwide,” said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca.

“These promising results show eplontersen has the potential to be a new and much needed treatment where limited options exist and significant unmet medical need remains.”

Related article: FDA Approves Alnylam’s Rare Disease RNAi Therapeutic 

 

Reducing TTR Protein Production and Slowing Disease Progression

 

The interim analysis, taken at 35 weeks, showed that eplontersen treatment led to a percent reduction in serum transthyretin (TTR) concentration in a statistically significant and clinically meaningful way, thereby reducing TTR protein production. 

The drug also reached its co-primary endpoint of change from baseline in a measure of neuropathic disease progression, versus an external placebo group. 

Patients treated with eplontersen also reported significantly improved quality of life versus placebo. In the trial, the drug showed a favorable safety and tolerability profile with no specific safety signals. 

 

Over $3 Billion on the Line for Eplontersen

 

Under terms of a deal established last year, AstraZeneca agreed to pay Ionis $200 million upfront to jointly develop and market eplontersen in the US. Furthermore, AstraZeneca will pay up to $485 million based on the regulatory progress of the drug. If approved, eplontersen could net Ionis up to $2.9 billion in sales milestones, plus royalties.

The deal also gave AstraZeneca rights to develop and market the drug in the rest of the world, except in Latin America.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Ionis Pharmaceuticals’ Factor XI Reduction Proved Effective in Trial
2022-11-07
The First Approved RSV Vaccine Worldwide Belongs to AstraZeneca and Sanofi
2022-11-06
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
LATEST
Junshi’s PD-1 Antibody Meets Endpoint In Phase 3 Lung Cancer Trial
2023-01-19
Moderna Welcomes Phase 3 Win For RSV Vaccine
2023-01-18
Moving Beyond COVID With mRNA Technology
2023-01-18
Rob Knight and Jing-Yuan Fu Elaborate On Microbiome Research Trends at the 7th Asia Microbiome Conference(AMC)
2023-01-17
CARsgen Taps Huadong to Commercialize Multiple Myeloma CAR-T in China
2023-01-17
Scientists Study Imaging Probes in First-Ever Amputated Human Limb Model
2023-01-16
EMA Plans to Issue Liver Failure Warning for Novartis’ Gene Therapy
2023-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!